Cite

HARVARD Citation

    Fleseriu, M. et al. (2022). Long-term outcomes of osilodrostat in Cushing's disease: LINC 3 study extension. European journal of endocrinology. 187 (4), pp. 531-541. [Online]. 
  
Back to record